330 related articles for article (PubMed ID: 33855089)
1. CAR T-Cell Production Using Nonviral Approaches.
Lukjanov V; Koutná I; Šimara P
J Immunol Res; 2021; 2021():6644685. PubMed ID: 33855089
[TBL] [Abstract][Full Text] [Related]
2. CAR T Cells Generated Using Sleeping Beauty Transposon Vectors and Expanded with an EBV-Transformed Lymphoblastoid Cell Line Display Antitumor Activity In Vitro and In Vivo.
Chicaybam L; Abdo L; Carneiro M; Peixoto B; Viegas M; de Sousa P; Fornazin MC; Spago MC; Albertoni Laranjeira AB; de Campos-Lima PO; Nowill A; Barros LRC; Bonamino MH
Hum Gene Ther; 2019 Apr; 30(4):511-522. PubMed ID: 30793967
[TBL] [Abstract][Full Text] [Related]
3. Minicircles for CAR T Cell Production by Sleeping Beauty Transposition: A Technological Overview.
Prommersberger S; Monjezi R; Shankar R; Schmeer M; Hudecek M; Ivics Z; Schleef M
Methods Mol Biol; 2022; 2521():25-39. PubMed ID: 35732991
[TBL] [Abstract][Full Text] [Related]
4. Generation of CAR+ T Lymphocytes Using the Sleeping Beauty Transposon System.
Chicaybam L; Abdo L; Bonamino MH
Methods Mol Biol; 2020; 2086():131-137. PubMed ID: 31707672
[TBL] [Abstract][Full Text] [Related]
5. Generation of CAR-T Cells with Sleeping Beauty Transposon Gene Transfer.
Prommersberger S; Monjezi R; Botezatu L; Miskey C; Amberger M; Mestermann K; Hudecek M; Ivics Z
Methods Mol Biol; 2022; 2521():41-66. PubMed ID: 35732992
[TBL] [Abstract][Full Text] [Related]
6. Minicircle-Based Engineering of Chimeric Antigen Receptor (CAR) T Cells.
Hudecek M; Gogishvili T; Monjezi R; Wegner J; Shankar R; Kruesemann C; Miskey C; Ivics Z; Schmeer M; Schleef M
Recent Results Cancer Res; 2016; 209():37-50. PubMed ID: 28101686
[TBL] [Abstract][Full Text] [Related]
7. Choosing the Right Tool for Genetic Engineering: Clinical Lessons from Chimeric Antigen Receptor-T Cells.
Irving M; Lanitis E; Migliorini D; Ivics Z; Guedan S
Hum Gene Ther; 2021 Oct; 32(19-20):1044-1058. PubMed ID: 34662233
[TBL] [Abstract][Full Text] [Related]
8. Generation of CAR-T Cells for Cancer Immunotherapy.
Xu Q; Harto H; Berahovich R; Xu S; Zhou H; Golubovskaya V; Wu L
Methods Mol Biol; 2019; 1884():349-360. PubMed ID: 30465215
[TBL] [Abstract][Full Text] [Related]
9. A new approach to CAR T-cell gene engineering and cultivation using piggyBac transposon in the presence of IL-4, IL-7 and IL-21.
Ptáčková P; Musil J; Štach M; Lesný P; Němečková Š; Král V; Fábry M; Otáhal P
Cytotherapy; 2018 Apr; 20(4):507-520. PubMed ID: 29475789
[TBL] [Abstract][Full Text] [Related]
10. The paths toward non-viral CAR-T cell manufacturing: A comprehensive review of state-of-the-art methods.
Metanat Y; Viktor P; Amajd A; Kaur I; Hamed AM; Abed Al-Abadi NK; Alwan NH; Chaitanya MVNL; Lakshmaiya N; Ghildiyal P; Khalaf OM; Ciongradi CI; Sârbu I
Life Sci; 2024 Jul; 348():122683. PubMed ID: 38702027
[TBL] [Abstract][Full Text] [Related]
11. Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells.
Morgan MA; Büning H; Sauer M; Schambach A
Front Immunol; 2020; 11():1965. PubMed ID: 32903482
[TBL] [Abstract][Full Text] [Related]
12. Nanotechnology and immunoengineering: How nanotechnology can boost CAR-T therapy.
Nawaz W; Xu S; Li Y; Huang B; Wu X; Wu Z
Acta Biomater; 2020 Jun; 109():21-36. PubMed ID: 32294554
[TBL] [Abstract][Full Text] [Related]
13. Optimized Production of Lentiviral Vectors for CAR-T Cell.
Moço PD; de Abreu Neto MS; Fantacini DMC; Picanço-Castro V
Methods Mol Biol; 2020; 2086():69-76. PubMed ID: 31707668
[TBL] [Abstract][Full Text] [Related]
14.
Suematsu M; Yagyu S; Nagao N; Kubota S; Shimizu Y; Tanaka M; Nakazawa Y; Imamura T
Front Immunol; 2022; 13():770132. PubMed ID: 35154098
[TBL] [Abstract][Full Text] [Related]
15. A new approach to gene therapy using Sleeping Beauty to genetically modify clinical-grade T cells to target CD19.
Singh H; Huls H; Kebriaei P; Cooper LJ
Immunol Rev; 2014 Jan; 257(1):181-90. PubMed ID: 24329797
[TBL] [Abstract][Full Text] [Related]
16. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
Front Immunol; 2018; 9():1717. PubMed ID: 30108584
[TBL] [Abstract][Full Text] [Related]
17. In Vitro Differentiation of T Cell: From CAR-Modified T-iPSC.
Ueda T; Kaneko S
Methods Mol Biol; 2019; 2048():85-91. PubMed ID: 31396933
[TBL] [Abstract][Full Text] [Related]
18. Transposon-Based CAR T Cells in Acute Leukemias: Where are We Going?
Magnani CF; Tettamanti S; Alberti G; Pisani I; Biondi A; Serafini M; Gaipa G
Cells; 2020 May; 9(6):. PubMed ID: 32471151
[TBL] [Abstract][Full Text] [Related]
19. Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using Sleeping Beauty system and artificial antigen presenting cells.
Singh H; Figliola MJ; Dawson MJ; Olivares S; Zhang L; Yang G; Maiti S; Manuri P; Senyukov V; Jena B; Kebriaei P; Champlin RE; Huls H; Cooper LJ
PLoS One; 2013; 8(5):e64138. PubMed ID: 23741305
[TBL] [Abstract][Full Text] [Related]
20. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
Gauthier J; Yakoub-Agha I
Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]